Cwm, LLC Precigen, Inc. Transaction History

Cwm, LLC

$23.3 Billion
Q3 2024

A detailed history of Cwm, LLC transactions in Precigen, Inc. stock. As of the latest transaction made, Cwm, LLC holds 43,054 shares of PGEN stock, worth $32,290. This represents 0.0% of its overall portfolio holdings.

Number of Shares

43,054

Previous 43,036 0.04%

Holding current value

$32,290

Previous $68,000 39.71%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 08, 2024	BUY	$0.91 - $1.88 $16 - $33	18 Added 0.04%	43,054 $41,000
Q2 2024 Jul 09, 2024	BUY	$1.27 - $1.75 $157 - $217	124 Added 0.29%	43,036 $68,000
Q4 2022 Feb 01, 2023	BUY	$1.27 - $2.26 $63 - $112	50 Added 0.12%	42,912 $65,000
Q2 2020 Sep 15, 2021	SELL	$2.16 - $5.46 $1,289 - $3,259	-597 Reduced 1.37%	42,862 $279,000
Q2 2020 Jul 22, 2020	BUY	$2.16 - $5.46 $1,289 - $3,259	597 Added 1.39%	43,459 $217,000
Q1 2020 Sep 15, 2021	SELL	$1.46 - $7.19 $871 - $4,292	-597 Reduced 1.37%	42,862 $279,000
Q1 2020 Apr 28, 2020	BUY	$1.46 - $7.19 $871 - $4,292	597 Added 1.39%	43,459 $148,000
Q4 2019 Sep 14, 2021	BUY	$5.01 - $6.58 $214,738 - $282,031	42,862 New	42,862 $279,000
Q4 2019 Jan 27, 2020	SELL	$5.01 - $6.58 $214,738 - $282,031	-42,862 Closed	0 $0
Q3 2019 Sep 14, 2021	BUY	$5.52 - $8.41 $236,598 - $360,469	42,862 New	42,862 $279,000
Q3 2019 Oct 22, 2019	SELL	$5.52 - $8.41 $236,598 - $360,469	-42,862 Closed	0 $0
Q2 2019 Sep 14, 2021	BUY	$4.11 - $8.6 $176,162 - $368,613	42,862 New	42,862 $279,000
Q2 2019 Jul 31, 2019	SELL	$4.11 - $8.6 $176,162 - $368,613	-42,862 Closed	0 $0
Q1 2019 Sep 02, 2021	BUY	$4.14 - $8.83 $177,448 - $378,471	42,862 New	42,862 $0

Others Institutions Holding PGEN

# of Institutions

143

Shares Held

159M

Call Options Held

232K

Put Options Held

69K

View Full List

About PRECIGEN, INC.

Ticker PGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 208,150,000
Market Cap $156M
Description
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorpora...

More about PGEN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cwm, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cwm, LLC with notifications on news.

Account